.Nature Medicine, Published online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized phase 3b/4 DESTINY-Breast12 study, trastuzumab deruxtecan (T-DXd) therapy of patients along with HER2+ advanced breast cancer cells as well as energetic or even steady brain metastases revealed regular intracranial activity and also systemic efficiency of T-DXd.